First author | Study | No. of patients | TNM stage | Treatment scheme | Overall survival | Locol control | Treatment failure | Toxicity (Grade≥3) |
---|---|---|---|---|---|---|---|---|
Shi XH [18] | Prospective | 43 | T1-4N0-1M0 | 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid | 5-year 34% | 5-year 55% | LR 41.8% (18/43) | PI 27.9% (12/43) |
DM 18.6% (8/43) | EI 34.9% (15/43) | |||||||
Wang Y [19] | Prospective | 52 | T1-4N0-1M0 | 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy,bid | 1-year 80.0% | 1-year 80.7% | LRF 13.5% (7/52) | PI 3.8% (2/52) |
EI 9.6% (5/52) | ||||||||
3-year 41.2% | 3-year 57.1% | DM 15.4% (8/52) | ES 1.9 % (1/52) | |||||
PF 0% (0/48) | ||||||||
EH 3.8% (2/52) | ||||||||
Zhao KL [20] | Retrospective | 56 | T1-2N0M0 | 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid | 1-year 90.9% | 1-year 90.9% | LR 12.5% (7/56) | PI 5.4 % (3/56) |
3-year 54.6% | 3-year 84.5% | DM 21.4% (12/56) | EI 10.7 % (6/56) | |||||
ES 1.8 % (/56) | ||||||||
5-year 47.8 % | 5-year 84.5 % | PF 1.8 % (/56) | ||||||
Zhao KL [21] | Retrospective | 201 | T1-4N0-1M0 | 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid | 1-year 73%, | 1-year 77% | LRF 38.4% (77/201) | EI 15.4% (31/201) |
PI 7.0% (14/201) | ||||||||
3-year 34%, | 3-year 58% | DM 34.9% (70/201) | EF 0.5% (1/201) | |||||
5-year 26% | 5-year 56% | |||||||
Zhao KL [22] | Prospective | 54 | T1-4N0-1M0 | 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid Plus ≥2 cycles of CHT with cisplatin+5-FU | 1-year 67%, | 1-year 84% | LRF 25.9% (14/54) | EI 24.1% (13/54) |
PI 5.5% (3/54) | ||||||||
3-year 44%, | 3-year 74% | PF 14.8% (8/54) | ||||||
5-year 40% | 5-year 67% | DM 24% (13/54) | ES 3.7% (2/54) | |||||
Wang JH [23] | Prospective | 48 | T1-4N0-1M0 | 40Gy/20fx followed by 21–27 Gy/14-18fx with 1.5Gy, bid | 1-year 79.2% | 1-year 81.3% | LR 35.4% (17/48) | PI 33.33% (16/48) |
EI 27.1% (13/48) | ||||||||
3-year 43.8% | 3-year 50.0% | DM 16.7% (8/48) | ES 14.6% (7/48) | |||||
PF 0% (0/48) |